The estimated Net Worth of Everett Cunningham is at least 9.45 百万$ dollars as of 30 April 2024. Everett Cunningham owns over 136 units of Arvinas Inc stock worth over 1,170,875$ and over the last 12 years Everett sold ARVN stock worth over 8,275,224$.
Everett has made over 15 trades of the Arvinas Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Everett sold 136 units of ARVN stock worth 8,180$ on 30 April 2024.
The largest trade Everett's ever made was selling 68,069 units of Arvinas Inc stock on 2 July 2018 worth over 7,465,127$. On average, Everett trades about 6,870 units every 65 days since 2013. As of 30 April 2024 Everett still owns at least 47,042 units of Arvinas Inc stock.
You can see the complete history of Everett Cunningham stock trades at the bottom of the page.
Everett's mailing address filed with the SEC is 5200 ILLUMINA WAY, , SAN DIEGO, CA, 92122.
Over the last 6 years, insiders at Arvinas Inc have traded over 123,187,141$ worth of Arvinas Inc stock and bought 3,567,290 units worth 69,124,444$ . The most active insiders traders include Capital Management, L.P.Ra ...、Liam Ratcliffe、Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of 1,884,820$. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth 244,472$.
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
Arvinas Inc executives and other stock owners filed with the SEC include: